ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE
Clinical trials for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE explained in plain language.
Never miss a new study
Get alerted when new ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE trials appear
Sign up with your email to follow new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for young patients battling tough lymphoma
Disease control OngoingThis study is testing a new treatment approach for children, teens, and young adults whose ALK-positive anaplastic large cell lymphoma has come back or hasn't responded to prior therapy. The treatment combines a newer immunotherapy drug (nivolumab) with chemotherapy, followed by …
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE
Phase: PHASE2 • Sponsor: New York Medical College • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
Targeted attack on rare blood cancers shows promise
Disease control OngoingThis study is testing a new treatment approach for aggressive types of T-cell lymphoma, a rare blood cancer. It combines a targeted drug that seeks out cancer cells with standard chemotherapy drugs. The goal is to see if this combination is safe and more effective at controlling …
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Virus + drug combo tested for Tough-to-Treat skin cancers
Disease control OngoingThis study is testing a two-part treatment for patients with advanced skin cancers or rare lymphomas that have not responded to other therapies. First, a modified virus is injected directly into tumors to help the immune system recognize cancer. Then, an immunotherapy drug is giv…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC